HEPION PHARMACEUTICALS INC. news, videos and press releases
For more news please use our advanced search feature.
HEPION PHARMACEUTICALS INC. - More news...
HEPION PHARMACEUTICALS INC. - More news...
- Hepion Pharmaceuticals to Present at the 7th Obesity & NASH Drug Development Summit
- Hepion Pharmaceuticals Announces Major Reductions in Liver Stiffness with Rencofilstat Treatment in 17-week Phase 2 Study of Advanced (F3) MASH Liver Disease
- Hepion Pharmaceuticals Schedules Conference Call to Review Additional Efficacy Data from Phase 2 ‘ALTITUDE-NASH’ Liver Function Trial of Rencofilstat
- Hepion Pharmaceuticals’ Rencofilstat Demonstrates Anti-Cancer Activity in Hepatitis C-Associated Cancer Model
- Hepion Pharmaceuticals Announces $5.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market under Nasdaq Rules
- Hepion Pharmaceuticals to Participate in 2023 Cantor Global Healthcare Conference
- New Anti-Cancer Opportunities Revealed for Hepion Pharmaceuticals’ Rencofilstat in Cancer Screening Program
- Hepion Pharmaceuticals Discovers Novel Rencofilstat Action in Liver Cancer
- Rencofilstat Produces Positive Outcomes in Translational Study on Idiopathic Pulmonary Fibrosis
- Hepion Pharmaceuticals Announces Management Changes
- Hepion Pharmaceuticals to Present Two Posters at EASL International Liver Congress™ 2023
- Hepion Pharmaceuticals Announces Passing of Key Safety Milestone in Phase 2b ‘ASCEND-NASH’ Trial of Rencofilstat
- Hepion Pharmaceuticals to Highlight AI-POWR™ at the 2023 CSPS Annual Symposium: The Next Frontiers in Pharmaceutical Sciences
- Hepion Pharmaceuticals’ Phase 2 ‘ALTITUDE-NASH’ Trial Achieves Primary and Secondary Endpoints, Including Improvement in Liver Function and Multiple NASH Biomarkers
- Hepion Pharmaceuticals Schedules Conference Call to Review Topline Results from Phase 2 ‘ALTITUDE-NASH’ Liver Function Trial of Rencofilstat
- Hepion Pharmaceuticals, Inc. Announces Reverse Stock Split
- Hepion Pharmaceuticals to Present Data on Synergistic Effects of Rencofilstat with Anti-PD1 at AACR 2023
- Hepion Pharmaceuticals Expands SAB with Appointments of Four Liver Disease KOLs
- Hepion Pharmaceuticals to Participate in ACS-JPS Webinar on AI Drug Development
- Hepion Pharmaceuticals to Deliver Updates on Ongoing Phase 2 NASH Clinical Program with Rencofilstat at 6th Global NASH Congress
- EPO Decision to Grant European Patent for Rencofilstat Further Strengthens Hepion’s Patent Portfolio
- Hepion Pharmaceuticals to Ring the NASDAQ Stock Market Closing Bell on February 10, 2023
- Anti-Cancer Potential of Rencofilstat Expanded with Results from Preclinical Multiple Myeloma Studies
- Presentation of Preclinical Study Highlighting Anti-Cancer Activity of Rencofilstat in Combination with Proteosome Inhibitors
- Hepion Pharmaceuticals Receives $3.2 Million in Aggregate Non-Dilutive Funding
- Hepion Pharmaceuticals to Present Phase 2a Rencofilstat Multiomics Data at NASH-TAG 2023
- Hepion Pharmaceuticals, Inc. Granted 180-day Extension by Nasdaq to Meet the Minimum Bid Price Requirements
- Hepion Pharmaceuticals Announces Early Completion of Enrollment in Phase 2 ‘ALTITUDE-NASH’ Liver Function Trial
- Hepion Pharmaceuticals Announces Pricing of $20.0 Million Private Placement of Convertible Redeemable Preferred Stock
- Hepion Pharmaceuticals to Present Two Posters at Upcoming AASLD The Liver Meeting® 2022
